Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ENTA
CUSIP:

Key Metrics:

Previous Close: $26.15
50 Day Moving Average: $23.46
200 Day Moving Average: $25.04
52-Week Range: $16.75 - $41.77
Trailing P/E Ratio: 17.29
Foreward P/E Ratio: -174.33
P/E Growth: 0.00
Market Cap: $497.77M
Outstanding Shares: 19,035,000
Beta: 0.58

Profitability:

Net Margins: 32.59%
Return on Equity: 11.31%
Return on Assets: 10.77%

Debt:

Current Ratio: 25.29%
Quick Ratio: 25.29%

Additional Links:

Companies Related to Enanta Pharmaceuticals:

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)

Ratings Breakdown:	1 Sell Rating, 2 Hold Ratings, 1 Buy Rating
Consensus Rating:	Hold (Score: 2.00)
Consensus Price Target:	$24.50 (6.31% downside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Show:

Date	Firm	Action	Rating	Price Target
8/9/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$31.00 -> $26.00
4/28/2016	JMP Securities	Downgrade	Outperform -> Market Perform
2/9/2016	Barclays PLC	Boost Price Target	Underweight	$16.00 -> $18.00
2/9/2016	Robert W. Baird	Reiterated Rating	Neutral	$36.00 -> $22.00
5/8/2015	Leerink Swann	Lower Price Target	Outperform	$42.00 -> $41.00
4/6/2015	Deutsche Bank AG	Initiated Coverage	Buy	$42.00 -> $42.00
11/24/2014	FBR & Co	Reiterated Rating	Outperform	$50.00

(Data available from 9/26/2014 forward)

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/21/2016
8/8/2016	Q216	($0.09)	($0.06)	$13.07 million	$14.00 million	View	Listen
5/9/2016	Q2	$0.10	($0.09)	$16.80 million	$13.00 million	View	Listen
2/8/2016	Q116	$1.13	$1.36	$47.32 million	$48.40 million	View	Listen
11/23/2015	Q415	$0.15	$0.29	$16.44 million	$14.40 million	View	Listen
8/6/2015	Q315	$0.19	$0.13	$16.18 million	$11.60 million	View	Listen
5/7/2015	Q215	$1.80	$1.49	$63.40 million	$57.40 million	View	Listen
2/5/2015	Q115	$3.82	$2.18	$86.62 million	$77.50 million	View	N/A
11/24/2014	Q414	($0.33)	($0.27)	$3.81 million	$2.60 million	View	Listen
8/11/2014	Q314	$1.67	$2.61	$40.83 million	$42.10 million	View	N/A
5/12/2014	Q2	$0.69	($0.28)	$1.20 million	$2.20 million	View	Listen
2/13/2014	Q114	($0.15)	($0.30)	$1.41 million	$0.89 million	View	N/A
11/25/2013	Q4	($0.29)	($0.25)	$1.00 million	$1.30 million	View	Listen
8/12/2013	Q213	($0.34)	($0.23)	$0.73 million	$1.60 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Current Year EPS Consensus Estimate: $1.02 EPS
Next Year EPS Consensus Estimate: $-0.15 EPS

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 70.82%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/11/2016	Nathaniel S Gardiner	VP	Buy	500	$24.45	$12,225.00
2/12/2016	Terry Vance	Director	Buy	2,000	$27.04	$54,080.00
11/24/2015	Paul J. Mellett	CFO	Sell	6,000	$30.15	$180,900.00
10/15/2015	Paul J Mellett	CFO	Sell	7,500	$40.10	$300,750.00
9/8/2015	Paul J. Mellett	CFO	Sell	7,500	$39.55	$296,625.00
7/13/2015	Paul J Mellett	CFO	Sell	7,500	$46.29	$347,175.00
7/13/2015	Yat Sun Or	Insider	Sell	3,750	$46.29	$173,587.50
6/11/2015	Paul J Mellett	CFO	Sell	7,500	$42.51	$318,825.00
6/11/2015	Yat Sun Or	Insider	Sell	3,750	$42.47	$159,262.50
6/5/2015	Yat Sun Or	Insider	Sell	10,750	$42.02	$451,715.00
5/19/2015	Paul J Mellett	CFO	Sell	24,000	$40.13	$963,120.00
5/11/2015	Yat Sun Or	Insider	Sell	8,000	$36.13	$289,040.00
3/9/2015	Jay R Luly	CEO	Sell	15,000	$33.37	$500,550.00
2/20/2015	Jay R Luly	CEO	Sell	15,000	$35.35	$530,250.00
2/19/2015	Stephen Jr. Buckley	Director	Buy	1,000	$34.00	$34,000.00
2/17/2015	Nathaniel S Gardiner	VP	Buy	1,400	$33.23	$46,522.00
1/16/2015	Paul J Mellett	CFO	Sell	4,500	$49.45	$222,525.00
1/5/2015	Jay R Luly	CEO	Sell	15,000	$50.43	$756,450.00
12/1/2014	Jay R Luly	CEO	Sell	15,000	$45.39	$680,850.00
11/3/2014	Jay R Luly	CEO	Sell	15,000	$42.52	$637,800.00
9/15/2014	Paul J Mellett	CFO	Sell	10,000	$39.83	$398,300.00
8/14/2014	Paul J Mellett	CFO	Sell	10,000	$39.13	$391,300.00
8/14/2014	Stephen Jr. Buckley	Director	Buy	1,000	$38.95	$38,950.00
7/14/2014	Paul J Mellett	CFO	Sell	20,000	$39.88	$797,600.00
5/1/2014	Yat Sun Or	Insider	Sell	5,000	$36.98	$184,900.00
4/1/2014	Jay Luly	CEO	Sell	15,000	$39.17	$587,550.00
4/1/2014	Yat Sun Or	Insider	Sell	10,000	$39.16	$391,600.00
3/24/2014	Yat Sun Or	Insider	Sell	10,000	$39.34	$393,400.00
3/4/2014	V Life Science Ventures Gm Tvm	major shareholder	Sell	439,334	$38.82	$17,054,945.88
2/26/2014	V Life Science Ventures Gm Tvm	major shareholder	Sell	230,190	$39.15	$9,011,938.50
2/24/2014	V Life Science Ventures Gm Tvm	major shareholder	Sell	60,477	$39.57	$2,393,074.89
2/14/2014	Jay Luly	CEO	Sell	5,800	$38.10	$220,980.00
1/2/2014	Jay R Luly	CEO	Sell	5,800	$28.05	$162,690.00
12/6/2013	Marc E Goldberg	Director	Sell	6,861	$27.93	$191,627.73
10/14/2013	Saints Capital Granite, L.P.	Major Shareholder	Sell	32,301	$19.84	$640,851.84
10/10/2013	Saints Capital Granite, L.P.	Major Shareholder	Sell	36,207	$21.71	$786,053.97
10/3/2013	Saints Capital Granite, L.P.	Major Shareholder	Sell	12,300	$23.39	$287,697.00
3/26/2013	Helmut Schuhsler	Director	Buy	132,949	$14.00	$1,861,286.00
3/26/2013	Saints Capital Granite, L.P.	Major Shareholder	Buy	66,474	$14.00	$930,636.00

(Data available from 1/1/2013 forward)

Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)

Date	Headline
	Enanta Pharmaceuticals Announces Data on Eight-Week Treatment … (NASDAQ:ENTA) www.tmcnet.com - September 24 at 4:37 PM
	6:08 am Enanta Pharmaceuticals announces new data showing high response rates with just eight weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) treatment (NASDAQ:ENTA) finance.yahoo.com - September 24 at 9:28 AM
	Enanta Pharma (ENTA) Announces New Data from VIEKIRAX + EXVIERA Phase 3 in Genotype 1b HCV - StreetInsider.com (NASDAQ:ENTA) www.streetinsider.com - September 23 at 4:36 PM
	Enanta Pharma (ENTA) Announces New Data from VIEKIRAX + EXVIERA Phase 3 in Genotype 1b HCV (NASDAQ:ENTA) www.streetinsider.com - September 23 at 9:50 AM
	Analyst Consensus Estimates & Projections are in For Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Frisco Fastball (NASDAQ:ENTA) friscofastball.com - September 22 at 10:26 AM
	Shares Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Expected To Hit $32 - Investor Newswire (NASDAQ:ENTA) www.investornewswire.com - September 22 at 10:26 AM
	Liver Disease Gets The Attention Of Several Major Biotech Companies (NASDAQ:ENTA) www.investors.com - September 21 at 5:22 PM
	Enanta Pharmaceuticals Inc. (ENTA) Has Re-crossed Its 200-Day Moving Average (NASDAQ:ENTA) www.rttnews.com - September 21 at 8:47 AM
	Stock Perspective: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings in View - Frisco Fastball (NASDAQ:ENTA) friscofastball.com - September 7 at 4:59 PM
	Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : September 7, 2016 (NASDAQ:ENTA) www.capitalcube.com - September 7 at 4:59 PM
	Shares Holding Above Moving Averages: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Post News (NASDAQ:ENTA) www.kentuckypostnews.com - August 29 at 3:53 PM
	ETF’s with exposure to Enanta Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:ENTA) www.capitalcube.com - August 29 at 3:53 PM
	Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences (NASDAQ:ENTA) www.businesswire.com - August 29 at 9:29 AM
	Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : August 26, 2016 (NASDAQ:ENTA) www.capitalcube.com - August 26 at 4:45 PM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ENTA) www.investornewswire.com - August 25 at 4:52 PM
	Crowd Views on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Post News (NASDAQ:ENTA) www.kentuckypostnews.com - August 23 at 4:56 PM
	ENANTA PHARMACEUTICALS INC Financials (NASDAQ:ENTA) finance.yahoo.com - August 18 at 4:51 PM
	Will Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Hit $32 Price Target? - Investor Newswire (NASDAQ:ENTA) www.investornewswire.com - August 17 at 5:02 PM
	ETF’s with exposure to Enanta Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:ENTA) www.capitalcube.com - August 12 at 4:53 PM
	Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : August 11, 2016 (NASDAQ:ENTA) www.capitalcube.com - August 11 at 4:59 PM
	Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2016 By the Numbers : August 10, 2016 (NASDAQ:ENTA) www.capitalcube.com - August 10 at 5:00 PM
	ENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ENTA) biz.yahoo.com - August 9 at 9:05 PM
	Edited Transcript of ENTA earnings conference call or presentation 8-Aug-16 8:30pm GMT (NASDAQ:ENTA) finance.yahoo.com - August 9 at 6:49 AM
	Enanta Pharmaceuticals : reports 3Q loss (NASDAQ:ENTA) www.4-traders.com - August 8 at 10:12 PM
	Enanta Pharmaceuticals Reports Financial ... (NASDAQ:ENTA) ih.advfn.com - August 8 at 4:58 PM
	Enanta Pharmaceuticals reports 3Q loss (NASDAQ:ENTA) sg.finance.yahoo.com - August 8 at 4:58 PM
	Q3 2016 Enanta Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ENTA) biz.yahoo.com - August 8 at 9:38 AM
	New Broker Ratings For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - FTSE News (NASDAQ:ENTA) www.ftsenews.co.uk - August 5 at 7:29 AM
	Enanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus (NASDAQ:ENTA) www.publicnow.com - August 2 at 9:38 AM
	Enanta Pharmaceuticals Inc. (ENTA) Jumps 7.1% on July 29 - Equities.com (NASDAQ:ENTA) www.equities.com - July 30 at 7:26 AM
	Can Shares Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Hit $32? - Investor Newswire (NASDAQ:ENTA) www.investornewswire.com - July 28 at 7:57 AM
	FDA Oks AbbVie' VIEKIRA XR To Treat Genotype 1 Chronic Hepatitis C Virus (NASDAQ:ENTA) www.nasdaq.com - July 26 at 7:41 AM
	Enanta Announces the U.S. Food and Drug … (NASDAQ:ENTA) www.tmcnet.com - July 25 at 10:20 PM
	CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) (NASDAQ:ENTA) finance.yahoo.com - July 25 at 4:00 AM
	Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Realized Volatility Hits An Elevated Level - CML News (NASDAQ:ENTA) news.cmlviz.com - July 23 at 8:55 AM
	Hays Advisory Lowers stake in Enanta Pharmaceuticals Inc (ENTA) - TheFounders Daily (NASDAQ:ENTA) www.thefoundersdaily.com - July 23 at 8:55 AM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ENTA) www.engelwooddaily.com - July 22 at 7:31 AM
	Enanta Pharmaceuticals Inc. (ENTA) Jumps 5.62% on July 21 - Equities.com (NASDAQ:ENTA) www.equities.com - July 22 at 7:31 AM
	Stock Soars, Rewards Investors Nicely Today: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily (NASDAQ:ENTA) www.engelwooddaily.com - July 21 at 5:00 PM
	ETF’s with exposure to Enanta Pharmaceuticals, Inc. : July 21, 2016 (NASDAQ:ENTA) www.capitalcube.com - July 21 at 1:59 PM
	Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for July 19 - Equities.com (NASDAQ:ENTA) www.equities.com - July 21 at 8:20 AM
	Is $32 Price Target Attainable For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)? - Investor Newswire (NASDAQ:ENTA) www.investornewswire.com - July 20 at 6:03 PM
	Equity Roundup: Stock Performance Focus on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph (NASDAQ:ENTA) presstelegraph.com - July 20 at 7:28 AM
	Enanta Pharmaceuticals to Host Conference Call on August … (NASDAQ:ENTA) www.tmcnet.com - July 19 at 10:05 PM
	Share Performance Summary for: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph (NASDAQ:ENTA) presstelegraph.com - July 18 at 9:57 AM
	Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016 (NASDAQ:ENTA) finance.yahoo.com - July 18 at 7:30 AM
	Shares Experiencing a Downtrend: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - TGP (NASDAQ:ENTA) telanaganapress.com - July 16 at 8:14 AM
	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ENTA) www.engelwooddaily.com - July 14 at 4:29 PM
	Enanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Short Interest Decreased By 1.75% - Consumer Eagle (NASDAQ:ENTA) www.consumereagle.com - July 14 at 4:29 PM
	Shares Losing Ground for the Month; Investor Alert on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily (NASDAQ:ENTA) www.engelwooddaily.com - July 14 at 8:03 AM